Compare
AbbVie vs Xencor (ABBV vs XNCR)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Xencor (XNCR) +148.8%; so far this year the figures are +27.5% and +133.5%.
AbbVie is the larger company by market value, about 192.1 times the size of Xencor.
Revenue grew +10.7% at ABBV and +33.5% at XNCR over the last year.
ABBV yields 2.38%. XNCR pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | XNCR | |
|---|---|---|
| Price | $291.31 | $35.75 |
| 1-day | +1.07% | +4.99% |
| YTD | +27.49% | +133.51% |
| 1 year | +34.39% | +148.78% |
| 3 years | +104.47% | +104.64% |
| Market cap | $514.9B | $2.7B |
| P/E | 50.1 | — |
| P/S | 7.80 | 13.38 |
| P/B | — | 4.79 |
| Revenue growth | +10.70% | +33.50% |
| EPS growth | +340.20% | — |
| Gross margin % | 73.7 | — |
| Net margin % | 15.7 | -58.8 |
| ROE % | — | -21.0 |
| Debt / equity | — | 0.17 |
| FCF yield % | 3.7 | -6.6 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 1.17 |
| RSI (14) | 59.7 | 76.7 |
| Technical rating |